In the first half of 2018, the net profit growth of five biomedical enterprises may exceed 1000%

[China Pharmaceutical network industry trends] according to statistics, as of July 19, 182 listed biomedical enterprises in Shanghai and Shenzhen have disclosed the mid-term performance forecast of 2018 147 enterprises, including those turning losses, are expected to achieve good results From the perspective of the change range of the predicted net profit, 136 enterprises achieved growth, only 7 of which lost money, excluding the enterprises with incomplete data According to the analysis of the insiders, in general, the half year performance of the biomedical sector is relatively good, and the proportion of loss making enterprises is not high In the first half of 2018, it is expected that the net profit of biomedical sector will increase in a large area in advance, with a significant increase, and the performance will be at a high level According to the forecast, there are 28 enterprises whose net profit changes by more than 100%, which means that the net profit of about 15% enterprises will double Among them, there are 5 companies with an increase rate of more than 1000%, including shengjitang, hiprec, berry gene, Boji medicine and meinian health It is estimated that in the first half of 2018, the company's net profit attributable to the shareholders of the listed company will be RMB 99.987 million to RMB 119.987 million, a year-on-year increase of 3248% to 3917% In the last half of this year, the urea and methanol markets recovered, the average price of products increased significantly year on year, and the gross profit of Sao Jitang chemical products increased by about 75-80 million yuan over the same period of last year At the same time, shengjitang's pharmaceutical business maintained a high-speed and stable growth, and the sales growth of traditional Chinese medicine and health care category was more prominent It is estimated that the net profit of pharmaceutical products will increase about 65 million to 70 million yuan year on year According to the forecast of the company's performance, the medium-term net profit is expected to increase by at least 26 times As a heparin API production and export enterprise with large domestic production, hapree has benefited from the improvement of supply and demand and the influence of industry recovery Since this year, the export price and export volume of heparin API have increased significantly, which has become the main reason for the company's performance to turn around Berry gene is a R & D biotech company that is committed to applying high-throughput gene sequencing technology to provide "non-invasive" overall solutions for clinical medical disease screening and diagnosis With years of technology accumulation and related research in tumor gene detection In the future, Beirui gene will also develop new early diagnosis technology according to the cancer disease map of Chinese people, so as to realize the clinical application of non-invasive early screening and diagnosis technology products as soon as possible, and benefit mankind Boji pharmaceutical released the half year performance forecast of 2018 on the evening of July 13 The company expects to achieve a net profit of 5.6494 million yuan to 6.1087 million yuan attributable to shareholders of Listed Companies in the first half of the year, an increase of 1130% to 1230% over the same period of last year The company said that the performance growth was mainly due to the gradual recovery of the company's profitability, and the increase in the income from clinical research services and pre clinical research services over the same period of last year, which led to a rise in net profit The company estimates that the impact of non recurring profit and loss on the net profit attributable to the shareholders of the listed company in the first half of the year is 700000-1200000 yuan Meinian health meinian health relies on a large number of physical examination population, massive health big data platform, and standardized medical service system all over the country, forming PDCA service closed-loop including industry inspection, risk assessment, health management and medical security The healthy ecosystem layout of meinian is becoming more and more perfect, with obvious advantages in data flow and artificial intelligence, so as to ensure sustained, high-speed and high-quality growth in the future.